SG11201803686UA - Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease - Google Patents
Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory diseaseInfo
- Publication number
- SG11201803686UA SG11201803686UA SG11201803686UA SG11201803686UA SG11201803686UA SG 11201803686U A SG11201803686U A SG 11201803686UA SG 11201803686U A SG11201803686U A SG 11201803686UA SG 11201803686U A SG11201803686U A SG 11201803686UA SG 11201803686U A SG11201803686U A SG 11201803686UA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- jak inhibitor
- compounds
- prodrugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259273P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/063254 WO2017091544A1 (en) | 2015-11-24 | 2016-11-22 | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803686UA true SG11201803686UA (en) | 2018-06-28 |
Family
ID=57518004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803686UA SG11201803686UA (en) | 2015-11-24 | 2016-11-22 | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10435428B2 (da) |
| EP (1) | EP3380486B1 (da) |
| JP (2) | JP6778747B2 (da) |
| KR (1) | KR20180080330A (da) |
| CN (1) | CN108290918B (da) |
| AU (1) | AU2016359494B2 (da) |
| BR (1) | BR112018010650A8 (da) |
| CA (1) | CA3003283A1 (da) |
| CL (1) | CL2018001345A1 (da) |
| CO (1) | CO2018005327A2 (da) |
| CY (1) | CY1122918T1 (da) |
| DK (1) | DK3380486T3 (da) |
| EA (1) | EA035816B1 (da) |
| ES (1) | ES2784523T3 (da) |
| HR (1) | HRP20200561T1 (da) |
| HU (1) | HUE049775T2 (da) |
| IL (1) | IL259076B (da) |
| LT (1) | LT3380486T (da) |
| ME (1) | ME03757B (da) |
| MX (1) | MX2018006282A (da) |
| MY (1) | MY189979A (da) |
| NZ (1) | NZ742574A (da) |
| PH (1) | PH12018501037A1 (da) |
| PL (1) | PL3380486T3 (da) |
| PT (1) | PT3380486T (da) |
| RS (1) | RS60237B1 (da) |
| SG (1) | SG11201803686UA (da) |
| SI (1) | SI3380486T1 (da) |
| TW (1) | TWI703147B (da) |
| UA (1) | UA121270C2 (da) |
| WO (1) | WO2017091544A1 (da) |
| ZA (1) | ZA201802967B (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3865481A1 (en) | 2015-11-03 | 2021-08-18 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| EP3371185B1 (en) | 2015-11-03 | 2020-09-30 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| HUE049775T2 (hu) | 2015-11-24 | 2020-10-28 | Theravance Biopharma R&D Ip Llc | Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei |
| FR3060567B1 (fr) * | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
| WO2018165250A1 (en) * | 2017-03-08 | 2018-09-13 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of tofacitinib |
| NZ759764A (en) | 2017-05-23 | 2022-07-01 | Theravance Biopharma R&D Ip Llc | Glucuronide prodrugs of janus kinase inhibitors |
| CN110662755A (zh) * | 2017-05-23 | 2020-01-07 | 施万生物制药研发Ip有限责任公司 | 托法替尼的硫代氨基甲酸酯前药 |
| CA3062067A1 (en) * | 2017-06-05 | 2018-12-13 | Flagship Pioneering Innovations V, Inc. | Multibiotic agents and methods of using the same |
| US10933069B2 (en) | 2018-01-05 | 2021-03-02 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| KR20190110459A (ko) * | 2018-03-20 | 2019-09-30 | 삼진제약주식회사 | 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| US20220257600A1 (en) | 2018-06-20 | 2022-08-18 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| CN111094314B (zh) * | 2018-08-15 | 2022-08-12 | 江苏豪森药业集团有限公司 | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 |
| KR20210074291A (ko) * | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
| CN109134564B (zh) * | 2018-09-21 | 2022-03-11 | 合肥锐思生物医药有限公司 | 乳果糖糖苷衍生物、其制备方法及其用途 |
| WO2020102519A1 (en) * | 2018-11-15 | 2020-05-22 | Janssen Biotech, Inc. | Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease |
| CN113692278A (zh) * | 2018-12-19 | 2021-11-23 | 因赛特公司 | 用于治疗胃肠道疾病的jak1途径抑制剂 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| TW202116778A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩二號公司 | 作為治療劑之細胞毒素之肽結合物 |
| EP3996749A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021231272A1 (en) * | 2020-05-14 | 2021-11-18 | Theravance Biopharma R&D Ip, Llc | Administration of gut-selective jak3 inhibitor |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| EP4232146A4 (en) * | 2020-10-22 | 2024-07-31 | Biora Therapeutics Inc | METHODS OF TREATMENT AND PREDICTION OF NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH DISEASES OF THE GASTROINTESTINAL TRACT |
| EP4351584A1 (en) * | 2021-06-07 | 2024-04-17 | The Regents of the University of California | Compositions and methods for treating celiac disease |
| WO2023225463A2 (en) * | 2022-05-14 | 2023-11-23 | 3-D Matrix, Ltd. | Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract |
| CN115073543B (zh) * | 2022-07-20 | 2022-11-15 | 北京普祺医药科技股份有限公司 | 一种jak抑制剂的化合物前药及其制备与应用 |
| CN117567460A (zh) * | 2022-08-08 | 2024-02-20 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022334A1 (en) | 1992-05-04 | 1993-11-11 | Sri International | Pharmaceutical compositions and methods for colonic delivery of corticosteroids |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| KR100477818B1 (ko) | 1999-12-10 | 2005-03-22 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-ｄ] 피리미딘 화합물 |
| JP5946768B2 (ja) | 2009-10-09 | 2016-07-06 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | ３−（４−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１Ｈ−ピラゾール−１−イル）−３−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体 |
| EP2515913A2 (en) | 2009-12-23 | 2012-10-31 | Glycomyr Inc. | Use of vitamin d glycosides and sulfates for treatment of disease |
| CN102724967A (zh) | 2009-12-31 | 2012-10-10 | 安龙制药公司 | 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物 |
| AU2011213198B2 (en) * | 2010-02-05 | 2014-04-24 | Zoetis Llc | Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors |
| US20130109720A1 (en) | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Indole inhibitors of crac |
| US20140357557A1 (en) * | 2013-05-31 | 2014-12-04 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| JP6697403B2 (ja) * | 2014-06-24 | 2020-05-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 炎症性腸疾患の処置のための方法及び医薬組成物 |
| HUE049775T2 (hu) | 2015-11-24 | 2020-10-28 | Theravance Biopharma R&D Ip Llc | Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei |
| AU2016379454B2 (en) | 2015-12-23 | 2021-01-28 | The University Of British Columbia | Lipid-linked prodrugs |
| CN106496233B (zh) | 2016-09-26 | 2018-05-15 | 东南大学 | 吡咯并嘧啶类化合物、其制备方法及其用途 |
-
2016
- 2016-11-22 HU HUE16808876A patent/HUE049775T2/hu unknown
- 2016-11-22 JP JP2018526682A patent/JP6778747B2/ja active Active
- 2016-11-22 CN CN201680068165.XA patent/CN108290918B/zh active Active
- 2016-11-22 UA UAA201806963A patent/UA121270C2/uk unknown
- 2016-11-22 WO PCT/US2016/063254 patent/WO2017091544A1/en active Application Filing
- 2016-11-22 TW TW105138180A patent/TWI703147B/zh not_active IP Right Cessation
- 2016-11-22 LT LTEP16808876.3T patent/LT3380486T/lt unknown
- 2016-11-22 EA EA201891248A patent/EA035816B1/ru unknown
- 2016-11-22 CA CA3003283A patent/CA3003283A1/en not_active Abandoned
- 2016-11-22 US US15/358,462 patent/US10435428B2/en active Active
- 2016-11-22 ES ES16808876T patent/ES2784523T3/es active Active
- 2016-11-22 RS RS20200508A patent/RS60237B1/sr unknown
- 2016-11-22 MX MX2018006282A patent/MX2018006282A/es unknown
- 2016-11-22 DK DK16808876.3T patent/DK3380486T3/da active
- 2016-11-22 SI SI201630741T patent/SI3380486T1/sl unknown
- 2016-11-22 MY MYPI2018701637A patent/MY189979A/en unknown
- 2016-11-22 ME MEP-2020-126A patent/ME03757B/me unknown
- 2016-11-22 SG SG11201803686UA patent/SG11201803686UA/en unknown
- 2016-11-22 BR BR112018010650A patent/BR112018010650A8/pt not_active IP Right Cessation
- 2016-11-22 KR KR1020187017879A patent/KR20180080330A/ko not_active Application Discontinuation
- 2016-11-22 PT PT168088763T patent/PT3380486T/pt unknown
- 2016-11-22 PL PL16808876T patent/PL3380486T3/pl unknown
- 2016-11-22 AU AU2016359494A patent/AU2016359494B2/en not_active Ceased
- 2016-11-22 NZ NZ742574A patent/NZ742574A/en unknown
- 2016-11-22 EP EP16808876.3A patent/EP3380486B1/en active Active
-
2018
- 2018-05-01 IL IL259076A patent/IL259076B/en active IP Right Grant
- 2018-05-07 ZA ZA2018/02967A patent/ZA201802967B/en unknown
- 2018-05-15 PH PH12018501037A patent/PH12018501037A1/en unknown
- 2018-05-18 CL CL2018001345A patent/CL2018001345A1/es unknown
- 2018-05-22 CO CONC2018/0005327A patent/CO2018005327A2/es unknown
-
2019
- 2019-08-29 US US16/555,222 patent/US10961267B2/en active Active
-
2020
- 2020-04-03 HR HRP20200561TT patent/HRP20200561T1/hr unknown
- 2020-05-13 CY CY20201100447T patent/CY1122918T1/el unknown
- 2020-08-25 JP JP2020141651A patent/JP2020196742A/ja active Pending
-
2021
- 2021-02-22 US US17/249,126 patent/US11608354B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201909841RA (en) | Antitumoral compounds | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease |